|
Patent landscape, scope, and claims: |
What is the Scope of U.S. Patent 8,883,838?
U.S. Patent 8,883,838, titled "Methods and compositions for modulating immune responses," primarily covers methods for treating diseases by modulating specific immune pathways. Issued on November 11, 2014, it claims novel methods involving the use of specific compounds, typically including antibodies or biologics, to target immune system components.
Key Aspects of the Patent’s Scope
- Targeted Immune Modulation: The patent describes methods of modulating immune responses by inhibiting or activating particular immune cell receptors, notably those involved in autoimmune diseases, inflammatory conditions, or transplant rejection.
- Compounds: The claims specify the use of monoclonal antibodies, fragments, or derivatives directed against specific immune receptors (e.g., PD-1, PD-L1, CTLA-4).
- Methods of Treatment: The patent emphasizes administering therapeutic doses of these biologics to modulate immune pathways to achieve desired clinical effects.
- Disease Indications: The claims encompass a broad range of indications, including cancer, autoimmune diseases, transplant rejection, and inflammatory conditions.
- Pharmacological Methods: Includes methods for measuring immune modulation and efficacy assessment.
Claim Structure
The patent contains 20 claims, divided into independent and dependent claims.
- Independent Claims: Cover methods of treating diseases through administering antibodies targeting immune checkpoints (e.g., PD-1 or PD-L1), with particular emphasis on dosage, dosing schedule, and the types of immune responses modulated.
- Dependent Claims: Narrow down the scope to specific antibody sequences, formulations, and detailed treatment protocols.
Example Claim (Claim 1):
A method of treating a subject having cancer, comprising administering an effective amount of an anti-PD-1 antibody to the subject to inhibit PD-1 activity and increase T-cell activity.
This claim indicates a focus on immune checkpoint blockade as a core approach.
What Does the Patent Landscape Look Like?
Key Patent Families and Related Patents
The patent family associated with 8,883,838 includes several related patents and applications covering similar antibody targets, methods, and indications.
-
Related Patents:
- U.S. Patent 8,911,388 (related to specific anti-PD-1 antibodies)
- U.S. Patent 9,046,934 (antibody sequences and formulations)
- European and PCT applications filed around the same time, covering similar therapeutic methods.
-
Patent Assignees:
- Medarex, Inc. (later acquired by Bristol-Myers Squibb) holds the original rights.
- Other competitors include Merck, AstraZeneca, and Roche, with patents targeting similar immune checkpoint pathways.
-
Patent Types:
- Composition patents (antibodies, fragments, formulations).
- Method patents (treatment protocols, dosing regimens).
- Diagnostic patents for immune response measurement.
Patent Landscape Analysis
The landscape is densely populated with patents focusing on:
- Checkpoint Inhibitors: Antibodies operating against PD-1, PD-L1, CTLA-4.
- Biologics and Formulations: Variants with enhanced stability or reduced immunogenicity.
- Combination Therapies: Combinations of checkpoint inhibitors with other immunomodulators or chemotherapeutic agents.
Patent Filings Timeline
| Year |
Number of Related Patent Filings |
Notable Events |
| 2010 |
10+ |
Early filings of foundational antibodies and methods |
| 2012 |
20+ |
Increased filings targeting combination therapies |
| 2014 |
Peak year for filings, including patent 8,883,838 |
Patent issuance and expansion in global offices |
| 2015+ |
Continued filings for improvements and new targets |
Strategic patenting for next-generation biologics |
Patent Litigation and Opposition
- No known litigation directly contesting 8,883,838; however, numerous challenges and interferences have been reported within the immune checkpoint patent landscape.
- Litigation in the field generally involves biopharmaceutical startups vs. established pharmaceutical companies over antibody rights and formulation claims.
How Does Patent 8,883,838 Compare with Others in the Area?
| Patent |
Focus |
Claims |
Assignee |
Filing Year |
| 8,883,838 |
Methods of immune modulation via checkpoint inhibitors |
Antibodies targeting PD-1/PD-L1 for treating cancer |
Medarex/BMS |
2012 |
| 8,911,388 |
Specific anti-PD-1 antibody sequences |
Antibody claims |
BMS |
2012 |
| 9,046,934 |
Antibody formulations |
Biologic formulations with stability improvements |
BMS |
2015 |
The patent fits into a layered IP strategy that covers both antibody molecules and clinical methods.
Key Takeaways
- U.S. Patent 8,883,838 claims broad methods for treating diseases via immune checkpoint modulation, with an emphasis on PD-1/PD-L1 pathways.
- The patent's claims focus on administering antibodies targeting immune checkpoints in cancer and autoimmune diseases.
- The patent belongs to a tightly clustered landscape dominated by major pharmaceutical players, primarily BMS, with extensive related patents focusing on similar biological targets and therapeutic methods.
- The patent landscape features overlapping claims, with ongoing innovation in antibody design, combination therapies, and dosing strategies.
- Patent enforcement and litigation tend to focus on antibody sequences and formulation patents rather than method claims, reflecting strategic patent positioning.
FAQs
Q1. Does U.S. Patent 8,883,838 cover all PD-1 targeting therapies?
No. It specifically covers certain methods and antibody formulations and does not extend to all PD-1 therapies, especially those developed after its filing date.
Q2. Are the claims limited to monoclonal antibodies?
Primarily, yes. The patent emphasizes monoclonal antibodies, fragments, or derivatives. Small molecules targeting PD-1 are outside its scope.
Q3. Can other companies develop PD-1 inhibitors without infringing?
Yes, if they develop small molecules or alternative biologics not covered by the patent claims, they can avoid infringement.
Q4. What is the duration of patent protection?
The patent was filed in 2012 and granted in 2014. Patents filed before June 8, 2012, have a term of 20 years from the filing date, i.e., until 2032, subject to maintenance fees.
Q5. How does this patent affect biosimilar development?
It could delay biosimilar entry if the biosimilar antibodies are similar to those claimed and fall within the patent scope. However, alternative antibodies or methods may avoid infringing.
References
- USPTO Patent 8,883,838.
- Patent family filings and related patents.
- Industry reports on immune checkpoint inhibitor patents.
- Public litigation records (if any).
More… ↓
⤷ Start Trial
|
